구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | durvalumab (Imfinzi, MEDI4736) AstraZeneca·PD-L1 750 trials·t½ ~21 days (10 mg/kg q2w historical; flat mg dosing per current label) | zanidatamab (Ziihera, ZW25, zanidatamab-hrii) Jazz Pharmaceuticals / Zymeworks·HER2 (biparatopic) 35 trials·t½ ~7 days |
|---|---|---|
Overview Program | Imfinzi (durvalumab) | Ziihera (zanidatamab) |
Overview Company | AstraZeneca | Jazz Pharmaceuticals / Zymeworks |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | PD-L1 | HER2 (biparatopic) |
Overview Indication | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC | First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract cancer |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m | Dual-epitope binding drives receptor clustering, faster internalization, and stronger signaling blockade than either monoclonal alone. In GEA the label splits IHC 3+ (chemo doublet) from IHC 3+ or 2+/ISH+ (chemo + Tevimbra). |
Positioning Known limitation | escape detection by the immune system | HER2 heterogeneity, PI3K pathway activation, and bypass RTK signaling. |
Positioning Development positioning | — | Challenges the ToGA trastuzumab-chemo backbone in 1L HER2+ GEA; still the only HER2 agent with a dedicated BTC indication. |
MoA Mechanism | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. | Simultaneous binding of two non-overlapping HER2 epitopes crosslinks adjacent receptors, causing receptor clustering, internalization, and degradation alongside ADCC and complement activity. |
MoA Biomarker | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. | GEA: PATHWAY 4B5 IHC and VENTANA Dual ISH. IHC 3+ for chemo doublet; IHC 3+ or IHC 2+/ISH+ when Tevimbra is added. BTC: HER2 IHC 3+. |
PK/PD Half-life | ~21 days (10 mg/kg q2w historical; flat mg dosing per current label) | ~7 days |
PK/PD Species | Mouse, OS and PFS benefit in PACIFIC, pCR rates in neoadjuvant trials | Cynomolgus monkey, Human, OS and PFS in GEA, ORR and DOR in BTC |
PK/PD Animal (cat.) | Mouse, In vitro | Human, NHP, In vitro |
PK/PD Experiment | PD | pd |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse | Human |
Toxicology Major finding | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. |
Toxicology CRS | N/A | N/A |
Clinical Safety signal | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. |
Clinical Selected reported efficacy | — | ORR 52% |
Clinical Reported ORR | 0% | 52% |
Clinical Reported PFS | — | ~5.5 mo |
Clinical Reported OS | — | 15.54 |
Clinical Result source | ClinicalTrials.gov NCT04372927 | HERIZON-BTC-01 (NCT04466891) |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04372927 | NCT04466891 |
Preclinical Animal (cat.) | — | Unknown |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | durvalumab (Imfinzi, MEDI4736) AstraZeneca·PD-L1 750 trials·t½ ~21 days (10 mg/kg q2w historical; flat mg dosing per current label) | zanidatamab (Ziihera, ZW25, zanidatamab-hrii) Jazz Pharmaceuticals / Zymeworks·HER2 (biparatopic) 35 trials·t½ ~7 days |
|---|---|---|
Overview Program | Imfinzi (durvalumab) | Ziihera (zanidatamab) |
Overview Company | AstraZeneca | Jazz Pharmaceuticals / Zymeworks |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | PD-L1 | HER2 (biparatopic) |
Overview Indication | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC | First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract cancer |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m | Dual-epitope binding drives receptor clustering, faster internalization, and stronger signaling blockade than either monoclonal alone. In GEA the label splits IHC 3+ (chemo doublet) from IHC 3+ or 2+/ISH+ (chemo + Tevimbra). |
Positioning Known limitation | escape detection by the immune system | HER2 heterogeneity, PI3K pathway activation, and bypass RTK signaling. |
Positioning Development positioning | — | Challenges the ToGA trastuzumab-chemo backbone in 1L HER2+ GEA; still the only HER2 agent with a dedicated BTC indication. |
MoA Mechanism | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. | Simultaneous binding of two non-overlapping HER2 epitopes crosslinks adjacent receptors, causing receptor clustering, internalization, and degradation alongside ADCC and complement activity. |
MoA Biomarker | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. | GEA: PATHWAY 4B5 IHC and VENTANA Dual ISH. IHC 3+ for chemo doublet; IHC 3+ or IHC 2+/ISH+ when Tevimbra is added. BTC: HER2 IHC 3+. |
PK/PD Half-life | ~21 days (10 mg/kg q2w historical; flat mg dosing per current label) | ~7 days |
PK/PD Species | Mouse, OS and PFS benefit in PACIFIC, pCR rates in neoadjuvant trials | Cynomolgus monkey, Human, OS and PFS in GEA, ORR and DOR in BTC |
PK/PD Animal (cat.) | Mouse, In vitro | Human, NHP, In vitro |
PK/PD Experiment | PD | pd |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse | Human |
Toxicology Major finding | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. |
Toxicology CRS | N/A | N/A |
Clinical Safety signal | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. |
Clinical Selected reported efficacy | — | ORR 52% |
Clinical Reported ORR | 0% | 52% |
Clinical Reported PFS | — | ~5.5 mo |
Clinical Reported OS | — | 15.54 |
Clinical Result source | ClinicalTrials.gov NCT04372927 | HERIZON-BTC-01 (NCT04466891) |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04372927 | NCT04466891 |
Preclinical Animal (cat.) | — | Unknown |
추천 비교
추천 비교